Artificial intelligence tools that millions rely on for quick health answers are failing at a critical task: determining whether a home blood pressure monitor has passed independent clinical validation. According to preliminary research presented at the American Heart Association's Hypertension Scientific Sessions 2026, three of the four most popular AI-powered search tools—ChatGPT, Microsoft Copilot, and Perplexity AI—accurately identified validated home blood pressure monitors only 63% to 83% of the time. Google Gemini performed better but still provided incorrect responses about 10% to 15% of the time.
The findings matter because high blood pressure affects more than 125 million U.S. adults, yet only about 1 in 4 of those adults have their blood pressure within the target range of less than 120/80 mm Hg. The 2025 American Heart Association Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults recommends using a validated home monitor, but the new study shows AI tools often misidentify devices that appear on official registries.
"We found that most AI tools performed only slightly better than if you had flipped a coin for each question," said Anna Soriano, M.D., a third-year internal medicine resident at the University of Montreal and the study's presenting author. "People may unknowingly think a device is validated based on the AI tool's inaccurate responses. Using that device may result in inaccurate blood pressure readings, which could lead to an inappropriate diagnosis or treatment decisions."
Researchers tested 324 home blood pressure monitors in Canada between April and May 2026—145 validated and 179 not validated—drawn from three validation registries, a list of known non-validated devices, and top-selling monitors on Amazon. Each device was queried using four AI tools with three types of questions. Even when AI tools located a device within an official registry, they often failed to interpret that listing as proof of validation.
"It is surprising, and almost counterintuitive, that AI tools had so much difficulty specifically identifying validated devices, since those devices are the ones with clear listings on official registries," Soriano said.
Keith C. Ferdinand, M.D., FAHA, a volunteer expert for the American Heart Association and vice chair of its 2025 High Blood Pressure Guideline, emphasized caution. "The potential shortcomings of AI demonstrated by this study's results should remind clinicians and the public that the use of AI for clinical decision-making requires caution," Ferdinand said. He added that home blood pressure devices need to be both validated and accurate, and that with proper technique and regular monitoring, readings from home devices are valuable for improving patient care.
The study's implications extend beyond individual patients. As AI-powered search becomes integrated into online platforms, inaccurate answers could lead to widespread use of unvalidated monitors, resulting in misdiagnosis or inappropriate treatment. The researchers advise healthcare professionals and the public to confirm validation through independent, free registries such as www.validatebp.org or validatebp.org. The American Heart Association also provides guidance on Home Blood Pressure Monitoring.
A limitation of the study is that results are likely to change as AI technology improves. The findings are considered preliminary until published as a full manuscript in a peer-reviewed journal. The abstract will be published in the Hypertension Scientific Sessions 2026 Supplement of the Hypertension journal. Additional resources include a Cuffless blood pressure technologies in wearable devices show promise to transform care and a report that Only 1 in 7 online health images show proper technique to accurately measure blood pressure. The original release is available on www.newmediawire.com.
